Single institutional experience of prevalence and risk factors of thromboembolic events in children with solid tumors

被引:2
|
作者
Raybagkar, Deepti A. [1 ]
Kohn, Nina [2 ]
Acharya, Suchitra S. [3 ]
机构
[1] St Christophers Hosp Children, Sect Hematol, Philadelphia, PA 19133 USA
[2] North Shore LIJ Hlth Syst, Feinstein Inst Med Res, Manhasset, NY USA
[3] Steven & Alexandra Cohen Childrens Med Ctr New Yo, Div Hematol Oncol & Stem Cell Transplant, New Hyde Pk, NY USA
关键词
thromboembolic events; solid tumors; metastatic disease; steroids; mediastinal mass; infection; central venous access device; ACUTE LYMPHOBLASTIC-LEUKEMIA; VENOUS THROMBOEMBOLISM; THROMBOSIS; COMPLICATIONS; CANCER; CHEMOTHERAPY; EPIDEMIOLOGY; PATHOGENESIS; ADOLESCENT; CISPLATIN;
D O I
10.1097/MBC.0000000000000038
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Children with cancer are long-term survivors and sequelae from thromboembolic events (TEEs) that include postthrombotic syndrome can cause significant morbidity. Prevalence and risk factors in children with solid tumors are not well described despite some recent studies. If risk factors were better defined, it may be possible to institute appropriate strategies to prevent TEEs and sequelae. A single institution study was performed to investigate the prevalence and risk factors of TEEs in pediatric solid tumors; this included a retrospective analysis of children with central nervous system (CNS) and non-CNS solid tumors with and without TEEs. TEEs were observed in 7.16% of analyzed tumors, higher in the non-CNS (10.6%) than in the CNS tumor category (1.9% P <0.0066). Factors associated with significant risk of TEEs are as follows: presence of a mediastinal mass (P = 0.0005), metastatic disease (P = 0.0086), infection (0.0120), central venous access device (CVAD) (P = 0.0167), and steroids as chemotherapy (P = 0.01). In patients with CVADs, a mediastinal mass (P = 0.0024) and the type of CVAD (peripherally inserted central catheters were more significant risk factors compared with Mediport; P < 0.0001) were significant risk factors. There was a 3.5-fold increased risk of TEEs in patients with CVADs with an underlying diagnosis of lymphoma vs. CNS tumors. Patients with non-CNS solid tumors had increased prevalence of TEEs in our study. Risk factors included metastatic disease, presence of a mediastinal mass, CVAD use, infection, and the use of steroids. Our study underscores the need to conduct a prospective study to formulate the use of prophylactic anticoagulation in patients with identified risk factors to prevent TEEs.
引用
收藏
页码:333 / 339
页数:7
相关论文
共 50 条
  • [21] The incidence and risk factors of thrombosis and the need for thromboprophylaxis in lymphoma and leukemia patients: A 9-year single-center experience
    Yildiz, Abdulkerim
    Albayrak, Murat
    Pala, Cigdem
    Ozturk, Hacer B. Afacan
    Maral, Senem
    Sahin, Osman
    Comert, Pinar
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2020, 26 (02) : 386 - 396
  • [22] The Effect of Nivolumab in Pediatric Malignant Tumors: A Single Center Experience with Nine Children
    Gok, Veysel
    Aydin, Firdevs
    Ozcan, Alper
    Karaman, Zehra Filiz
    Yilmaz, Ebru
    Gorukmez, Orhan
    Gorukmez, Ozlem
    Bisgin, Atil
    Karakukcu, Musa
    Patiroglu, Turkan
    Unal, Ekrem
    UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2024, 34 (04): : 184 - 194
  • [23] Risk factors for venous thromboembolic events in pediatric surgical patients: Defining indications for prophylaxis
    Cairo, Sarah B.
    Lautz, Timothy B.
    Schaefer, Beverly A.
    Yu, Guan
    Naseem, Hibbut-ur-Rauf
    Rothstein, David H.
    JOURNAL OF PEDIATRIC SURGERY, 2018, 53 (10) : 1996 - 2002
  • [24] Incidence of venous thromboembolic events in cancer patients receiving immunotherapy: a single-institution experience
    L. Gutierrez-Sainz
    V. Martinez-Marin
    D. Viñal
    D. Martinez-Perez
    J. Pedregosa
    J. A. Garcia-Cuesta
    J. Villamayor
    P. Zamora
    A. Pinto
    A. Redondo
    B. Castelo
    P. Cruz
    O. Higuera
    A. Custodio
    A. Gallego
    D. Sanchez-Cabrero
    J. de Castro-Carpeño
    E. Espinosa
    J. Feliu
    Clinical and Translational Oncology, 2021, 23 : 1245 - 1252
  • [25] Prevalence and risk factors for venous thromboembolic complications in the Swiss Inflammatory Bowel Disease Cohort
    Alatri, Adriano
    Schoepfer, Alain
    Fournier, Nicolas
    Engelberger, Rolf Peter
    Safroneeva, Ekaterina
    Vavricka, Stephan
    Biedermann, Luc
    Calanca, Luca
    Mazzolai, Lucia
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2016, 51 (10) : 1200 - 1205
  • [26] Preventing treatment abandonment for children with solid tumors: A single-center experience in Brazil
    Ferman, Sima
    da Silva Lima, Fernanda Ferreira
    Souza Lage, Carollyne Rodrigues
    da Hora, Senir Santos
    Vianna, Danielle Tavares
    Thuler, Luiz Claudio
    PEDIATRIC BLOOD & CANCER, 2019, 66 (07)
  • [27] Risk factors associated with cisplatin-induced ototoxicity in Japanese patients with solid tumors
    Okada, Hideaki
    Kitagawa, Koichi
    CANCER MEDICINE, 2023, 12 (07): : 7904 - 7910
  • [28] Management and investigation of neonatal thromboembolic events: Genetic and acquired risk factors
    Saracco, P.
    Parodi, E.
    Fabris, C.
    Cecinati, V.
    Molinari, A. C.
    Giordano, P.
    THROMBOSIS RESEARCH, 2009, 123 (06) : 805 - 809
  • [29] Thromboembolic Events Following Splenectomy: Risk Factors, Prevention, Management and Outcomes
    Rottenstreich, Amihai
    Kleinstern, Geffen
    Spectre, Galia
    Da'as, Nael
    Ziv, Esther
    Kalish, Yosef
    WORLD JOURNAL OF SURGERY, 2018, 42 (03) : 675 - 681
  • [30] Accumulation of risk factors increases risk of thromboembolic events in patients with nonvalvular atrial fibrillation
    Inoue, Hiroshi
    Nozawa, Takashi
    Hirai, Tadakazu
    Iwasa, Atsushi
    Okumura, Ken
    Lee, Jong-Dae
    Shimizu, Akihiko
    Hayano, Motonobu
    Yano, Katsusuke
    CIRCULATION JOURNAL, 2006, 70 (06) : 651 - 656